直 Japanese PDF Font
  • 구성원
  • 업무분야
  • 소식 및 자료
  • 사무소
  • Firm
  • 채용공고
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • 생명과학
    • Transportation and Logistics
  • 업무사례

특허 무효심판(PTAB) 소송절차 : 당사자계 무효심판(IPR), 등록 후 무효심판(PGR)

About

PTAB pioneers representing both petitioners and patent owners 
Our professionals have handled more than 1,400 cases before the Patent Trial and Appeal Board (PTAB) at the U.S. Patent and Trademark Office (USPTO)—we know our way around the PTAB’s unique procedures and potential pitfalls. In handling inter partes review (IPR), post-grant review (PGR), and covered business method review (CBM) proceedings, there are many opportunities for a procedural misstep or strategic miscalculation. The administrative patent judges are patent attorneys with science and technology backgrounds. They can and often do get into the weeds about the patented technology, prior art, and PTAB procedures. When arguing before the Board, a detailed understanding of both the technology and the law is essential. While we have been recognized as the most experienced firm in representing petitioners, a distinguishing feature of our practice is that we also devote a significant portion of our practice to defending patent owners. Our experience on both sides of the table allows us to be an objective resource for clients facing post-grant challenges.

Efficiently coordinate parallel proceedings across teams

Routinely scrutinizing the rules, requirements, and nuances of each proceeding, as well as the PTAB’s evolving guidelines, positions Finnegan to counsel clients on the best tools for challenging the patents at issue, or likewise, fending off attacks. We approach cases with lean teams of attorneys that bring a mix of procedural insight, knowledge of the technology at issue, and trial experience briefing and arguing cases before the Board. Our PTAB practitioners are well versed in coordinating across attorney teams handling related litigation in district court or before the International Trade Commission (ITC), whether the team is from Finnegan or another law firm. This integrated approach allows us to provide clients with effective, efficient representation in all PTAB proceedings.

Subscribe to At the PTAB Blog

On our At the PTAB Blog, we publish a subset of the USPTO’s PTAB data we track monthly, as well as posts summarizing and analyzing PTAB news and information. We also publish a subset of our cumulative PTAB data here.

Everyone in this practice

업무사례

Carrum Technologies, LLC v. BMW of North America, LLC, et al.

Obtained complete victory against Carrum on appeal of the District of Delaware’s claim construction to the Federal Circuit following Carrum’s stipulation of non-infringement under the claim construction, thereby exonerating BMW’s ACC system, first sold in 2000, against Carrum’s 2004 patents. Invalidated several asserted claims through post-grant efforts before the U.S. Patent Office, including IPRs and EPRs, and pursued claims through proceedings before the Eastern District of Virginia to vindicate BMW’s patent challenges.

1:18-cv-01645, D. Del., Judge Andrews
21-1435, 24-1480, Fed. Cir., Judges Clevenger, Cunningham, Lourie, Moore, Prost, Taranto
IPR2019-00902, -00903, -00904, -00905, -00927, 00928, PTAB, Judges Browne, Scanlon, Tornquist
90/019,010, CRU

Eye Therapies, LLC v. Slayback Pharma, LLC

Finnegan represented Bausch & Lomb’s licensee Eye Therapies, LLC in an appeal at the U.S. Court of Appeals for the Federal Circuit from a Patent Trial and Appeal Board (PTAB) decision finding Eye Therapies’ patent directed to a low-dose brimonidine treatment for eye redness (Lumify®) to be unpatentable. In a precedential decision, the Federal Circuit agreed with Finnegan’s arguments and found that the Board had wrongly invalidated the patent based on an incorrect claim construction, vacating and remanding the case back to the PTAB. The proceeding settled shortly thereafter

23-2173, Fed. Cir., Judges Taranto, Stoll, Scarsi

Jumio Corporation v. FaceTec, Inc.

Representing FaceTec, Inc. in four inter partes reviews (IPRs) relating to groundbreaking 3D liveness detection technology.

IPR2025-00106, -00107, -00108, -00109, PTAB, Judges Khan, Hoang, Baer

BMW of North America, LLC and Bayerische Motoren Werke AG v. Arigna Technology Ltd.

Secured a covenant-not-to-sue and zero-dollar walkaway for BMW Group in a declaratory judgment action, concluding Arigna’s high-profile patent enforcement campaign involving current amplification technology. This outcome follows a decisive ITC victory, the dismissal of parallel District Court litigation, and multiple concurrent patent office challenges pending at the time of resolution.

1:23-cv-01190, D.D.C., Judge Contreras
2:21-cv-00173, E.D. Tex.
IPR2021-01531, PTAB, Judges Baer, Fenick, Iftikhar
23-1931, Fed. Cir.
90/019,261, USPTO

Maxeon Solar PTE, Ltd., v. REC Solar Holdings AS 
Represented REC before the U.S. District Court for the Eastern District of Texas and in parallel IPR filings regarding TOPCon solar cells.

2:24-cv-00260, E.D. Tex., Judge Gilstrap
IPR2025-00592, -00593, -00594, -00595, PTAB

Bell Northern Research, LLC v. MediaTek Inc. et al.
Obtained favorable settlement prior to trial at the U.S. International Trade Commission (ITC) after obtaining a finding of indefiniteness of one of three asserted patents, institution of inter partes review (IPR) of another patent, and filing an offensive case seeking damages, inter alia, in the form of attorneys’ fees for being forced to defend against Bell Northern’s assertion of patents in violation of FRAND licensing obligations.

337-TA-1367, ITC, Judge Moore
2:23-cv-10783, C.D. Cal., Judges Anelle-Rocha, Eick
IPR2023-01414, PTAB, Judges Abraham, Cass, Hamann

More

Insights

At the PTAB Blog

Federal Circuit PTAB Appeal Statistics for March–May 2026

July 2, 2026

At the PTAB Blog

Deadline Evolution: Director Extends Deadline for Requesting Director Review of Institution Grants to 30 Days

June 30, 2026

At the PTAB Blog

New Informative Decision Applies the USPTO’s U.S. Manufacturing and Small Business Use of AIA Proceedings Memo

June 18, 2026

Federal Circuit IP Blog

Federal Circuit Reinforces Injury-in-Fact Requirement in Appeals from Post-Grant Proceedings

June 10, 2026

Federal Circuit IP Blog

Spotlight on Upcoming Oral Arguments – June 2026

June 8, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

More

Upcoming Events

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

뉴스

Award/Ranking

Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers

June 22, 2026

Award/Ranking

Finnegan Earns Top Rankings in the 2026 Legal 500 U.S. Guide

June 10, 2026

Award/Ranking

Forbes Names Finnegan Partner Erika Harmon Arner on its Inaugural 2026 America’s Top Women Lawyers List

June 5, 2026

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Commentary

Litigation Leaders: Finnegan’s Jennifer Roscetti on the Advantages of Being Fully Focused on IP

April 6, 2026

Commentary

Squires’ Latest PTAB Memo Seeks to Boost U.S. Manufacturing with New Discretionary Factors

March 18, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 개인정보처리방침
  • 면책공고
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP